NGM Biopharmaceuticals Inc
F:0IK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NGM Biopharmaceuticals Inc
Income from Continuing Operations
NGM Biopharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NGM Biopharmaceuticals Inc
F:0IK
|
Income from Continuing Operations
$21.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$21B
|
CAGR 3-Years
25%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
$7.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
NGM Biopharmaceuticals Inc
Glance View
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The Company’s robust portfolio of product candidates include NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, a key component of the tumor stroma, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.
See Also
What is NGM Biopharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
21.7m
USD
Based on the financial report for Dec 31, 2025, NGM Biopharmaceuticals Inc's Income from Continuing Operations amounts to 21.7m USD.
What is NGM Biopharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
8%
Over the last year, the Income from Continuing Operations growth was 85%. The average annual Income from Continuing Operations growth rates for NGM Biopharmaceuticals Inc have been 8% over the past three years .
